Menu

Dying Light Marks the Spot

Drug-delivering nanoparticles designed to glow when their target cells die can report on the effectiveness of cancer therapies within just a few hours of treatment, a mouse study shows.

Mar 29, 2016
Catherine Offord

Nanoparticles glow fluorescent green as cells sensitive to drugs produce the capsase enzyme. BRIGHAM AND WOMEN’S HOSPITAL, ASHISH KULKARNIMost methods traditionally used to monitor the effectiveness of a cancer treatment, such as positron emission tomography (PET) and magnetic resonance imaging (MRI) scans, detect decreases in tumor size only after several rounds of therapy. But researchers at Brigham and Women’s Hospital in Boston  have now developed a technique that causes drug-transporting nanoparticles to glow with fluorescence as their target cells die, making it possible to visualize the effectiveness of a therapy much sooner than with standard methods. The team described its technique in a mouse study published yesterday (March 28) in PNAS.

“Using this approach, the cells light up the moment a cancer drug starts working,” study coauthor Shiladitya Sengupta of Brigham and Women’s said in a statement. “We can determine if a cancer therapy is effective within hours of treatment.”

In the new method, tested in tumor-bearing mice, the researchers used nanoparticles of approximately 100 nanometers in diameter to deliver both a cytotoxic drug and a fluorescent reporter to tumor cells. The fluorescent reporter had been designed to glow only in the presence of capsase—an enzyme produced when cells die, thus producing a visual indicator of a treatment’s success within only a few hours of its administration.

After trialing the method with both a common chemotherapeutic agent, paclitaxel, and an anti-PD-L1 immunotherapy, “we’ve demonstrated that this technique can help us directly visualize and measure the responsiveness of tumors to both types of drugs,” study coauthor Ashish Kulkarni at Brigham and Women’s said in the statement.

One potential drawback to the technology is that the imaging chemicals themselves can be toxic, Mansoor Amiji of Northeastern University who was not involved in the research told Science News. But developing a real-time measurement of a drug’s performance is an important step, he said. “There’s a tremendous need, especially as we think about personalizing cancer therapies.”

The research is at the proof-of-concept stage, Sengupta told Science News, but future work will aim to translate the findings to humans. “Our long-term goal is to find a way to monitor outcomes very early so that we don’t give a chemotherapy drug to patients who are not responding to it,” he said.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing